Quantcast

Latest Aratana Therapeutics Inc. Stories

2014-07-02 08:26:23

KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the...

2014-06-23 16:25:15

KANSAS CITY, Kan., June 23, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors. Mr. Roche has extensive operational and product launch expertise working for leading pharmaceutical...

2014-06-19 16:26:30

KANSAS CITY, Kan., June 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will participate in two upcoming investor conferences. Aratana will provide an overview of its business during a live presentation at the JMP Securities Healthcare Conference and will be available to...

2014-06-18 16:26:53

KANSAS CITY, Kan., June 18, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of...

2014-06-09 08:29:12

Data Presented from Company's Pain, Cancer Immunotherapy, and Inappetence Programs KANSAS CITY, Kan., June 9, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced findings from the company's ongoing safety and clinical programs, which were presented at the 2014 American College of Veterinary...

2014-05-30 08:25:24

KANSAS CITY, Kan., May 30, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will participate in two upcoming investor conferences. Aratana will provide an overview of its business during a live presentation and will be available to participate in one-on-one meetings with investors who...

2014-05-23 12:24:37

KANSAS CITY, Kan., May 23, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will participate in two upcoming investor conferences. Aratana will provide an overview of its business and participate in one-on-one meetings with investors who are registered to attend the conferences....

2014-05-13 16:28:32

--Conference Call Today, May 13, 2014, 4:45 p.m. Eastern Time-- KANSAS CITY, Kan., May 13, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results. "Aratana continues to advance its deep pipeline of therapeutics focused on treating serious diseases in pets," stated...

2014-05-12 08:31:24

Product is being developed to treat pain in dogs with osteoarthritis KANSAS CITY, Kan., May 12, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company's innovative drug for treating pain in dogs...

2014-05-05 08:24:39

Conference Call and Webcast scheduled for May 13, 2014, 4:45 p.m. ET KANSAS CITY, Kan., May 5, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:45 p.m. ET, to discuss its financial results for the quarter ended March 31, 2014....


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related